Consilium MedicumConsilium MedicumConsilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum56786610.26442/20751753.2023.5.202272ArticlesСтатьиReview ArticleNon-alcoholic fatty liver disease: from understanding risk factors to finding optimal treatment regimens: A reviewНеалкогольная жировая болезнь печени: от понимания факторов риска к поиску оптимальных схем терапииhttps://orcid.org/0000-0002-7628-8851TeplyukDaria A.ТеплюкДарья Андреевна
Russian Federation

Assistant

ассистент каф. терапии ИПО

teplyouk@gmail.comhttps://orcid.org/0009-0008-6250-1448KaisinaAliya A.КайсинаАлия Абай кызы
Kazakhstan

Doctoral Student

докторант каф. гастроэнтерологии

teplyouk@gmail.comhttps://orcid.org/0000-0002-9509-2643IbragimovaShabnam I.ИбрагимоваШабнам Илдырым кызы
Russian Federation

Graduate Student

аспирант каф. терапии ИПО

teplyouk@gmail.comhttps://orcid.org/0000-0001-7551-1268BestavashviliAfina A.БеставашвилиАфина Автандиловна
Russian Federation

Res. Officer

науч. сотр. Института персонализированной кардиологии Центра «Цифровой биодизайн и персонализированное здравоохранение»

teplyouk@gmail.comhttps://orcid.org/0000-0002-6960-1184TinkovaIrina O.ТиньковаИрина Олеговна
Russian Federation

Pathologist

врач-патологоанатом патологоанатомического отд-ния

teplyouk@gmail.comhttps://orcid.org/0000-0003-1949-914XPashkovaEvgeniia Iu.ПашковаЕвгения Юрьевна
Russian Federation

Cand. Sci. (Med.)

канд. мед. наук, зав. эндокринологическим отд-нием №59

teplyouk@gmail.comhttps://orcid.org/0000-0002-0783-4441KaibullayevaJamilya A.КайбуллаеваДжамиля Ахтановна
Kazakhstan

Cand. Sci. (Med.)

канд. мед. наук, доц. каф. гастроэнтерологии

teplyouk@gmail.comhttps://orcid.org/0000-0002-8601-3966NersesovAlexander V.НерсесовАлександр Витальевич
Kazakhstan

D. Sci. (Med.), Prof.

д-р мед. наук, проф., зав. каф. гастроэнтерологии

teplyouk@gmail.comhttps://orcid.org/0000-0001-5031-9798PavlovChavdar S.ПавловЧавдар Савов
Russian Federation

D. Sci. (Med.), Prof.

д-р мед. наук, проф., зав. каф. терапии ИПО

teplyouk@gmail.comSechenov First Moscow State Medical University (Sechenov University)ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)Asfendiyarov Kazakh National Medical UniversityНАО «Казахский национальный медицинский университет им. С.Д. Асфендиярова»Botkin State Clinical HospitalГБУЗ «Государственная клиническая больница им. С.П. Боткина» Департамента здравоохранения г. Москвы15052023255GastroenterologyГастроэнтерология3253323007202330072023Copyright ©; 2023, Consilium MedicumCopyright ©; 2023, ООО "Консилиум Медикум"2023Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://consilium.orscience.ru/2075-1753/article/view/567866

Non-alcoholic fatty liver disease (NAFLD) is now a major risk factor for death among patients with liver disease. Currently, drugs that primarily affect surrogate markers of NAFLD are available. However, none of these drugs showed a significant effect on the course of steatohepatitis and fibrogenesis. The search for the most relevant lifestyle modification programs is still a priority in comprehensive treatment. A clinical case of follow-up of a comorbid patient is presented. Despite comprehensive treatment, disease regression was not achieved. NAFLD therapy remains a relevant issue. Finding new ways to affect the NAFLD course and individualize treatment approaches is necessary.

Неалкогольная жировая болезнь печени (НАЖБП) в настоящее время является одним из основных факторов риска смерти среди пациентов с заболеванием печени. На данный момент в арсенале современного клинициста есть лекарственные средства, влияющие в первую очередь на суррогатные маркеры НАЖБП. Однако ни один из этих препаратов не оказал значимого влияния на течение стеатогепатита и фиброгенез. Поиск наиболее актуальных программ модификации образа жизни по-прежнему стоит на первом месте комплексного лечения пациента. Представлен клинический случай динамического наблюдения коморбидного больного. Несмотря на комплексное лечение, добиться регресса заболевания не удалось. Терапия НАЖБП остается значимой проблемой. Необходимы поиск новых путей воздействия на течение НАЖБП и индивидуализация подходов к лечению.

non-alcoholic fatty liver diseasecomorbidityhepatoprotective agentstreatmentнеалкогольная жировая болезнь печеникоморбидностьгепатопротекторылечениеRiazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7:851-61. DOI:10.1016/S2468-1253(22)00165-0Valencia-Rodríguez A, Vera-Barajas A, Chávez-Tapia NC, et al. Looking into a new era for the approach of metabolic (dysfunction) associated fatty liver disease. Ann Hepatol. 2020;19:227-9. DOI:10.1016/j.aohep.2020.04.001López-Velázquez JA, Silva-Vidal KV, Ponciano-Rodríguez G, et al. The prevalence of nonalcoholic fatty liver disease in the Americas. Ann Hepatol. 2014;13:166-78. DOI:10.1016/s1665-2681(19)30879-8Perumpail BJ, Khan MA, Yoo ER, et al. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol. 2017;23:8263-76. DOI:10.3748/wjg.v23.i47.8263Maurice J, Manousou P. Non-alcoholic fatty liver disease. Clin Med. 2018;18:245-50. DOI:10.7861/clinmedicine.18-3-245Mendez-Sanchez N, Arrese M, Gadano A, et al. The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease. Lancet Gastroenterol Hepatol. 2021;6:65-72. DOI:10.1016/S2468-1253(20)30340-XYounossi Z, Tacke F, Arrese M, et al. Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Hepatology. 2019;69:2672-82. DOI:10.1002/hep.30251Torres DM, Williams CD, Harrison SA. Features, Diagnosis, and Treatment of Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2012;10:837-58. DOI:10.1016/j.cgh.2012.03.011Nasr P, Ignatova S, Kechagias S, Ekstedt M. Natural history of nonalcoholic fatty liver disease: A prospective follow-up study with serial biopsies. Hepatol Commun. 2018;2:199-210. DOI:10.1002/hep4.1134Leung C, Yeoh SW, Patrick D, et al. Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-alcoholic fatty liver disease. World J Gastroenterol. 2015;21:1189-96. DOI:10.3748/wjg.v21.i4.1189Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology. 2010;52:1836-46. DOI:10.1002/hep.24001Vilar-Gomez E, Calzadilla-Bertot L, Wai-Sun Wong V, et al. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study. Gastroenterology. 2018;155:443-57.e17. DOI:10.1053/j.gastro.2018.04.034Ballestri S, Zona S, Targher G, et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol. 2016;31:936-44. DOI:10.1111/jgh.13264Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease – Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73-84. DOI:10.1002/hep.28431Masarone M, Rosato V, Aglitti A, et al. Liver biopsy in type 2 diabetes mellitus: Steatohepatitis represents the sole feature of liver damage. PLoS One. 2017;12:1-10. DOI:10.1371/journal.pone.0178473Haffner SM. Pre-diabetes, insulin resistance, inflammation and CVD risk. Diabetes Res Clin Pract. 2003;61 Suppl. 1:S9-18. DOI:10.1016/s0168-8227(03)00122-0Sasso FC, Pafundi PC, Marfella R, et al. Adiponectin and insulin resistance are related to restenosis and overall new PCI in subjects with normal glucose tolerance: The prospective AIRE Study. Cardiovasc Diabetol. 2019;18:1-13. DOI:10.1186/s12933-019-0826-0Stols-Gonçalves D, Hovingh GK, Nieuwdorp M, Holleboom AG. NAFLD and Atherosclerosis: Two Sides of the Same Dysmetabolic Coin? Trends Endocrinol Metab. 2019;30:891-902. DOI:10.1016/j.tem.2019.08.008Targher G, Lonardo A, Byrne CD. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. Nat Rev Endocrinol. 2018;14:99-114. DOI:10.1038/nrendo.2017.173Alexander M, Loomis AK, Fairburn-Beech J, et al. Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease. BMC Med. 2018;16:1-11. DOI:10.1186/s12916-018-1103-xCharoenngam N, Holick MF. Immunologic effects of vitamin d on human health and disease. Nutrients. 2020;12:1-28. DOI:10.3390/nu12072097Eslam M, Sanyal AJ, George J, et al. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020;158:1999-2014.e1. DOI:10.1053/j.gastro.2019.11.312Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73:202-9. DOI:10.1016/j.jhep.2020.03.039Nseir W, Artul S, Nasrallah N, Mahamid M. The association between primary bacteremia of presumed gastrointestinal origin and nonalcoholic fatty liver disease. Dig Liver Dis. 2016;48:343-4. DOI:10.1016/j.dld.2015.10.004Boursier J, Mueller O, Barret M, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology. 2016;63:764-75. DOI:10.1002/hep.28356Saltzman ET, Palacios T, Thomsen M, Vitetta L. Intestinal microbiome shifts, dysbiosis, inflammation, and non-alcoholic fatty liver disease. Front Microbiol. 2018;9:1-11. DOI:10.3389/fmicb.2018.00061Mendez-Sanchez N, Cruz-Ramon VC, Ramirez-Perez OL, et al. New aspects of lipotoxicity in nonalcoholic steatohepatitis. Int J Mol Sci. 2018;19. DOI:10.3390/ijms19072034Fedchuk L, Nascimbeni F, Pais R, et al. Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2014;40:1209-22. DOI:10.1111/apt.12963Marchesini G, Day CP, Dufour JF, et al. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388-402. DOI:10.1016/j.jhep.2015.11.004Jennison E, Patel J, Scorletti E, Byrne CD. Diagnosis and management of non-alcoholic fatty liver disease. Postgrad Med J. 2019;95:314-22. DOI:10.1136/postgradmedj-2018-136316Fan JG, Kim SU, Wong VWS. New trends on obesity and NAFLD in Asia. J Hepatol. 2017;67(4):862-73.Hydes TJ, Summers N, Brown E, et al. Mechanisms, screening modalities and treatment options for individuals with non-alcoholic fatty liver disease and type 2 diabetes. Diabet Med. 2020;37(11):1793-806.Zhang C, Yang M. Current options and future directions for nafld and nash treatment. Int J Mol Sci. 2021;22. DOI:10.3390/ijms22147571Trauner M, Fuchs CD. Novel therapeutic targets for cholestatic and fatty liver disease. Gut. 2022;71:194-209. DOI:10.1136/gutjnl-2021-324305Marchesini G, Day CP, Dufour JF, et al. EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease. Obes Facts. 2016;9:65-90. DOI:10.1159/000443344Hallsworth K, Thoma C, Hollingsworth KG, et al. Modified high-intensity interval training reduces liver fat and improves cardiac function in non-alcoholic fatty liver disease: A randomized controlled trial. Clin Sci. 2015;129:1097-105. DOI:10.1042/CS20150308Coppel J, Hennis P, Gilbert-Kawai E, Grocott MPW. The physiological effects of hypobaric hypoxia versus normobaric hypoxia: A systematic review of crossover trials. Extrem Physiol Med. 2015;4. DOI:10.1186/s13728-014-0021-6Greer SN, Metcalf JL, Wang Y, Ohh M. The updated biology of hypoxia-inducible factor. EMBO J. 2012;31:2448-60. DOI:10.1038/emboj.2012.125Arkhipenko YV, Sazontova TG, Zhukova AG. Adaptation to periodic hypoxia and hyperoxia improves resistance of membrane structures in heart, liver, and brain. Bull Exp Biol Med. 2005;140:278-81. DOI:10.1007/s10517-005-0466-0Mallet RT, Manukhina EB, Ruelas SS. Cardioprotection by Intermittent Hypoxia Conditioning: Evidence, Mechanisms and Therapeutic Potential. Anal. Standar Pelayanan Minimal Pada Instal. Rawat Jalan di RSUD Kota Semarang. 2015;3:103-11.Burtscher J, Maglione V, Di Pardo A, et al. Rationale for hypoxic and chemical conditioning in Huntington’s disease. Int J Mol Sci. 2021;22:1-22. DOI:10.3390/ijms22020582Burtscher J, Syed MMK, Lashuel HA, Millet GP. Hypoxia Conditioning as a Promising Therapeutic Target in Parkinson’s Disease? Mov Disord. 2021;36:857-61. DOI:10.1002/mds.28544Camacho-Cardenosa A, Camacho-Cardenosa M, Brooks D, et al. Effects training in hypoxia on cardiometabolic parameters in obese people: A systematic review of randomized controlled trial. Aten Primaria. 2019;51:397-405. DOI:10.1016/j.aprim.2018.03.011Qin L, Xiang Y, Song Z, et al. Erythropoietin as a possible mechanism for the effects of intermittent hypoxia on bodyweight, serum glucose and leptin in mice. Regul Pept. 2010;165:168-73. DOI:10.1016/j.regpep.2010.07.163Sazontova TG, Stryapko NV, Arkhipenko YV. Addition of Hyperoxic Component to Adaptation to Hypoxia Prevents Impairments Induced by Low Doses of Toxicants (Free Radical Oxidation and Proteins of HSP Family). Bull Exp Biol Med. 2016;160:304-7. DOI:10.1007/s10517-016-3157-0He F, Ru X, Wen T. NRF2, a transcription factor for stress response and beyond. Int J Mol Sci. 2020;21:1-23. DOI:10.3390/ijms21134777Glazachev O, Kopylov P, Susta D, et al. Adaptations following an intermittent hypoxia-hyperoxia training in coronary artery disease patients: a controlled study. Clin Cardiol. 2017;40:370-6. DOI:10.1002/clc.22670Dudnik E, Zagaynaya E, Glazachev OS, Susta D. Intermittent hypoxia-hyperoxia conditioning improves cardiorespiratory fitness in older comorbid cardiac outpatients without hematological changes: A randomized controlled trial. High Alt Med Biol. 2018;19:339-43. DOI:10.1089/ham.2018.0014Tuter DS, Kopylov PY, Syrkin AL, et al. Intermittent systemic hypoxic-hyperoxic training for myocardial protection in patients undergoing coronary artery bypass surgery: First results from a single-centre, randomised controlled trial. Open Hear. 2018;5:1-8. DOI:10.1136/openhrt-2018-000891Buang Y, Wang YM, Cha JY, et al. Dietary phosphatidylcholine alleviates fatty liver induced by orotic acid. Nutrition. 2005;21:867-73. DOI:10.1016/j.nut.2004.11.019Lee HS, Nam Y, Chung YH, et al. Beneficial effects of phosphatidylcholine on high-fat diet-induced obesity, hyperlipidemia and fatty liver in mice. Life Sci. 2014;118:7-14. DOI:10.1016/j.lfs.2014.09.027Gundermann KJ, Gundermann S, Drozdzik M, Mohan Prasad VG. Essential phospholipids in fatty liver: A scientific update. Clin Exp Gastroenterol. 2016;9:105-17. DOI:10.2147/CEG.S96362Dajani AI, Popovic B. Essential phospholipids for nonalcoholic fatty liver disease associated with metabolic syndrome: A systematic review and network meta-analysis. World J Clin Cases. 2020;8:5235-49. DOI:10.12998/wjcc.v8.i21.5235Maev IV, Samsonov AA, Palgova LK, et al. Effectiveness of phosphatidylcholine in alleviating steatosis in patients with non-alcoholic fatty liver disease and cardiometabolic comorbidities (MANPOWER study). BMJ Open Gastroenterol. 2020;7:1-10. DOI:10.1136/bmjgast-2019-000341Le P, Chaitoff A, Rothberg MB, et al. Trends in pioglitazone use among U.S. adults with type 2 diabetes and suspected nonalcoholic fatty liver disease. Expert Opin Investig. Drugs. 2020;29:205-8. DOI:10.1080/13543784.2020.1704731Corey KE, Wilson LA, Altinbas A, et al. Relationship between resolution of non-alcoholic steatohepatitis and changes in lipoprotein sub-fractions: a post-hoc analysis of the PIVENS trial. Aliment Pharmacol Ther. 2019;49:1205-13. DOI:10.1111/apt.15216Gawrieh S, Wilson LA, Yates KP, et al. Relationship of ELF and PIIINP With Liver Histology and Response to Vitamin E or Pioglitazone in the PIVENS Trial. Hepatol Commun. 2021;5:786-97. DOI:10.1002/hep4.1680Brunt EM, Kleiner DE, Wilson LA, et al. Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials. Hepatology. 2019;70:522-31. DOI:10.1002/hep.30418Lian J, Fu J. Pioglitazone for NAFLD Patients With Prediabetes or Type 2 Diabetes Mellitus: A Meta-Analysis. Front Endocrinol (Lausanne). 2021;12:1-12. DOI:10.3389/fendo.2021.615409Ratziu V, Giral P, Jacqueminet S, et al. Rosiglitazone for Nonalcoholic Steatohepatitis: One-Year Results of the Randomized Placebo-Controlled Fatty Liver Improvement With Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology. 2008;135:100-10. DOI:10.1053/j.gastro.2008.03.078Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005-23. DOI:10.1002/hep.25762Gurka MJ, Mack JA, Chi X, DeBoer MD. Use of metabolic syndrome severity to assess treatment with vitamin E and pioglitazone for non-alcoholic steatohepatitis. J Gastroenterol Hepatol. 2021;36:249-56. DOI:10.1111/jgh.15131Bril F, Biernacki DM, Kalavalapalli S, et al. Role of Vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes: A randomized controlled trial. Diabetes Care. 2019;42:1481-8. DOI:10.2337/dc19-0167Singh S, Osna NA, Kharbanda KK. Treatment options for alcoholic and non-alcoholic fatty liver disease: A review. World J Gastroenterol. 2017;23:6549-70. DOI:10.3748/wjg.v23.i36.6549Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679-90. DOI:10.1016/S0140-6736(15)00803-XGastaldelli A, Repetto E, Guja C, et al. Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes. Diabetes Obes Metab. 2020;22(3):393-403. DOI:10.1111/dom.13907Liu L, Yan H, Xia M, et al. Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes. Diabetes Metab Res Rev. 2020;36(5):e3292. DOI:10.1002/dmrr.3292Mantovani A, Petracca G, Beatrice G, et al. Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials. Metabolites. 2021;11(2):73. DOI:10.3390/metabo11020073Bray JJH, Foster-Davies H, Salem A, et al. Glucagon-like peptide-1 receptor agonists improve biomarkers of inflammation and oxidative stress: A systematic review and meta-analysis of randomised controlled trials. Diabetes Obes Metab. 2021;23(8):1806-22. DOI:10.1111/dom.14399Vašura A, Blaho M, Dítě P, et al. Adiponektin u nemocných s metabolickým syndromem a chorobami jater, žlučových cest a pankreatu [Adiponectin in patients with metabolic syndrome and diseases of the liver, bile ducts and pancreas (in Polish)]. Vnitr Lek. 2018;63(12):945-4.Tas E, Bai S, Ou X, et al. Fibroblast Growth Factor-21 to Adiponectin Ratio: A Potential Biomarker to Monitor Liver Fat in Children With Obesity. Front Endocrinol (Lausanne). 2020;11:654. DOI:10.3389/fendo.2020.00654Chellali S, Boudiba A, Griene L, Koceir EA. Interactions incrétines-adipocytokines chez le sujet diabétique de type 2 avec ou sans stéatose hépatique non alcoolique : intérêt du GLP-1 (glucagon-like peptide-1) comme biomarqueur modulateur [Incretins-adipocytokines interactions in type 2 diabetic subjects with or without non-alcoholic fatty liver disease: interest of GLP-1 (glucagon-like peptide-1) as a modulating biomarker (in French)]. Ann Biol Clin (Paris). 2019;77(3):261-71. DOI:10.1684/abc.2019.1436de Carvalho CP, Marin DM, de Souza AL, et al. GLP-1 and adiponectin: effect of weight loss after dietary restriction and gastric bypass in morbidly obese patients with normal and abnormal glucose metabolism. Obes Surg. 2009;19(3):313-20. DOI:10.1007/s11695-008-9678-5Xiong X, Lu W, Qin X, et al. Downregulation of the GLP-1/CREB/adiponectin pathway is partially responsible for diabetes-induced dysregulated vascular tone and VSMC dysfunction. Biomed Pharmacother. 2020;127:110218. DOI:10.1016/j.biopha.2020.110218Patel V, Joharapurkar A, Kshirsagar S, et al. Coagonist of GLP-1 and Glucagon Receptor Ameliorates Development of Non-Alcoholic Fatty Liver Disease. Cardiovasc Hematol Agents Med Chem. 2018;16(1):35-43. DOI:10.2174/1871525716666180118152158Simental-Mendía LE, Sánchez-García A, Linden-Torres E, Simental-Mendía M. Impact of glucagon-like peptide-1 receptor agonists on adiponectin concentrations: A meta-analysis of randomized controlled trials. Br J Clin Pharmacol. 2021;87(11):4140-9. DOI:10.1111/bcp.14855Scheen AJ. Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2020;16(10):556-77. DOI:10.1038/s41574-020-0392-2Phrueksotsai S, Pinyopornpanish K, Euathrongchit J, et al. The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2021;36:2952-9. DOI:10.1111/jgh.15580Ghosh A, Dutta K, Bhatt SP, et al. Dapagliflozin Improves Body Fat Patterning, and Hepatic and Pancreatic Fat in Patients With Type 2 Diabetes in North India. J Clin Endocrinol Metab. 2022;107(6):e2267-75. DOI:10.1210/clinem/dgac138Kahl S, Gancheva S, Straßburger K, et al. Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial. Diabetes Care. 2020;43(2):298-305. DOI:10.2337/dc19-064181 Aso Y, Kato K, Sakurai S, et al. Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease. Int J Clin Pract. 2019;73(5):e13335. DOI:10.1111/ijcp.13335Sattar N, Fitchett D, Hantel S, et al. Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial. Diabetologia. 2018;61(10):2155-63. DOI:10.1007/s00125-018-4702-3Akuta N, Kawamura Y, Fujiyama S, et al. SGLT2 Inhibitor Treatment Outcome in Nonalcoholic Fatty Liver Disease Complicated with Diabetes Mellitus: The Long-term Effects on Clinical Features and Liver Histopathology. Intern Med. 2020;59(16):1931-7. DOI:10.2169/internalmedicine.4398-19Wang Y, Xia N. Influence of Sodium-Glucose Cotransporter-2 Inhibitors on Plasma Adiponectin in Patients with Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials. Horm Metab Res. 2022;54(12):833-44. DOI:10.1055/a-1897-6121Xiao MW, Lin SX, Shen ZH, et al. Systematic Review with Meta-Analysis: The Effects of Probiotics in Nonalcoholic Fatty Liver Disease. Gastroenterol Res Pract. 2019;2019:1484598. DOI:10.1155/2019/1484598Horvath A, Durdevic M, Leber B, et al. Changes in the Intestinal Microbiome during a Multispecies Probiotic Intervention in Compensated Cirrhosis. Nutrients. 2020;12(6):1874. DOI:10.3390/nu12061874Cai GS, Su H, Zhang J. Protective effect of probiotics in patients with non-alcoholic fatty liver disease. Medicine (Baltimore). 2020;99(32):e21464. DOI:10.1097/MD.0000000000021464Loman BR, Hernández-Saavedra D, An R, Rector RS. Prebiotic and probiotic treatment of nonalcoholic fatty liver disease: a systematic review and meta-analysis. Nutr Rev. 2018;76(11):822-39. DOI:10.1093/nutrit/nuy031Mei L, Tang Y, Li M, et al. Co-Administration of Cholesterol-Lowering Probiotics and Anthraquinone from Cassia obtusifolia L. Ameliorate Non-Alcoholic Fatty Liver. PLoS One. 2015;10(9):e0138078. DOI:10.1371/journal.pone.0138078Xue L, He J, Gao N, et al. Probiotics may delay the progression of nonalcoholic fatty liver disease by restoring the gut microbiota structure and improving intestinal endotoxemia. Sci Rep. 2017;7:45176. DOI:10.1038/srep45176Jena PK, Sheng L, Li Y, Wan YY. Probiotics VSL#3 Are Effective in Reversing Non-Alcoholic Steatohepatitis in a Mouse Model. Hepatobiliary Surg Nutr. 2020;9:170-82.Kim DH, Kim H, Jeong D, et al. Kefir alleviates obesity and hepatic steatosis in high-fat diet-fed mice by modulation of gut microbiota and mycobiota: targeted and untargeted community analysis with correlation of biomarkers. J Nutr Biochem. 2017;44:35-43. DOI:10.1016/j.jnutbio.2017.02.014Loomba R, Seguritan V, Li W, et al. Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. Cell Metab. 2017;25(5):1054-62.e5. DOI:10.1016/j.cmet.2017.04.001Chen Y, Yang F, Lu H, et al. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology. 2011;54(2):562-72. DOI:10.1002/hep.24423Shen F, Zheng RD, Sun XQ, et al. Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease. Hepatobiliary Pancreat Dis Int. 2017;16(4):375-81. DOI:10.1016/S1499-3872(17)60019-5